4-(3-Dimethylamino-propionyl)-benzonitrile | 133712-59-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(3-Dimethylamino-propionyl)-benzonitrile
• 英文别名: 4-(N,N-Dimethyl-beta-alanyl)benzonitrile；4-[3-(dimethylamino)propanoyl]benzonitrile
• CAS: 133712-59-1
• 化学式: C₁₂H₁₄N₂O
• 分子量: 202.256
• InChiKey: NBOVCDNQGHVTME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-Dimethylamino-propionyl)-benzonitrile 、 亚甲基三苯基膦烷 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 4-(Dimethylamino)-2-(4-cyanophenyl)-1-butene
  参考文献：
  名称：

  Photocyclization of 4-(dialkylamino)-2-aryl-1-butenes

  摘要：

  Irradiation of 4-(dialkylamino)-2-aryl-1-butenes gave cyclization products, 3-methyl-3-arylpyrrolidines, in high yields. These styrylamines formed fluorescent intramolecular exciplexes, but studies based on Stern-Volmer quenching for the fluorescence and the photoreaction suggested that the emissive exciplexes did not participate in the photoreaction.

  DOI：

  10.1021/jo00037a017

文献信息

• Aryloxyphenylpropylamines their preparation and use
  申请人：NOVO NORDISK A/S

  公开号：EP0399504A2

  公开（公告）日：1990-11-28

  Novel aryloxyphenylpropylamines having the formula wherein X is H, cyano, halogen, halogenoalkyl, C₁₋₆-alkoxy, C₁₋₆-alkyl, C₁₋₅-alkanoyl, C₃₋₅-alkylene, aryloxy or aralkoxy, and R is 3,4-methylenedioxy, aryl or heteroaryl which are optionally substituted with one or more cyano, halogeno, C₁₋₆-alkyl, C₁₋₆-alkoxy, C₁₋₆-alkenyl, trifluoromethyl, C₃₋₅- alkylene, aryloxy or aralkoxy: and R¹ and R² independently is C₁₋₁₀-alkyl, C₃₋₇-cycloalkyl, C₂₋₁₀-alkenyl, C₃₋₆-cycloalkyl-C₁₋₅-alkyl, optionally substituted with C₁₋₅-alkoxy or cyano; or R¹ and R² may together form a carbocyclic ring and a salt thereof with a pharmaceutically acceptable acid, provided however that R¹ is not C₃₋₇-cycloalkyl, C₁₋₁₀-alkyl, or alkenyl which may be straight, branched or cyclic, unsubstituted or substituted with C₁₋₄-alkoxy, aryloxy or cycloalkyl or cycloalkylalkyl, when X is H and R² is a methyl group. The novel compounds are useful in the treatment of anoxia, migraine, ischemia, epilepsy, traumatic injury and neurodegenerative diseases.

  具有以下式子的新型芳氧基苯基丙胺 其中 X 是 H、氰基、卤素、卤代烷基、C₁₋₆-烷氧基、C₁₋₆-烷基、C₁₋₅-烷酰基、C₃₋₅-亚烷基、芳氧基或芳烷氧基，以及 R 是 3,4-亚甲基二氧基、芳基或杂芳基，它们任选被一个或多个氰基、卤素、C₃₋₅烷基、芳氧基或芳烷氧基取代、C₁₋₆-烷基、C₁₋₆-烷氧基、C₁₋₆-烯基、三氟甲基、C₃₋₅-亚烷基、芳氧基或芳烷氧基取代：和 R¹ 和 R² 独立地是 C₁₋₁₀-烷基、C₃₋₇-环烷基、C₂₋₁₀-烯基、C₃₋₆-环烷基-C₁₋₅-烷基，任选被 C₁₋₅- 烷氧基或氰基取代； 或 R¹ 和 R² 可共同形成一个碳环及其与药学上可接受的酸的盐、 但是，当 X 为 H 且 R² 为甲基时，R¹ 不是 C₃₋₇-环烷基、C₁₋₁₀-烷基或烯基（可以是直链、支链或环链、未取代或被 C₁₋₄-烷氧基、芳氧基或环烷基或环烷基烷基取代）。 这些新型化合物可用于治疗缺氧、偏头痛、缺血、癫痫、外伤和神经退行性疾病。
• US5145870A
  申请人：——

  公开号：US5145870A

  公开（公告）日：1992-09-08
• US5310756A
  申请人：——

  公开号：US5310756A

  公开（公告）日：1994-05-10
• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSÉS PHARMACEUTIQUES
  申请人：SENTINEL ONCOLOGY LTD

  公开号：WO2021058754A1

  公开（公告）日：2021-04-01

  The invention provides a composition of matter which: • (i) consists of at least 90 % by weight of an atropisomer (2A) and 0-10 % by weight of an atropisomer of formula (2B); or • (ii) consists of at least 90 % by weight of an atropisomer (2B) and 0-10 % by weight of an atropisomer of formula (2A); wherein the atropisomer of formula (2A) and the atropisomer of formula (2B) are represented by: formula (2A) and formula (2B) or are pharmaceutically acceptable salts or tautomers thereof, wherein ring X is a benzene or pyridine ring; ring Y is selected from a benzene ring, a pyridine ring and a thiophene ring; R1 is trifluoromethyl; R2 is hydrogen; R3 is hydrogen; m is 0 or 1; n is 0, 1 or 2; Ar1 is a monocyclic aromatic ring selected from benzene and pyridine; each monocyclic aromatic ring being unsubstituted or substituted with 1 or 2 substituents R5 as defined herein; and R4; R5 when present, R6 and R7 independently selected from various substituents as defined herein. Also provided are individual atropisomers thereof as well as of various compounds having a five-membered heteroaromatic ring containing 1 or 2 nitrogen atoms or 1 nitrogen and 1 oxygen atom, with three rings Ar1, X and Y, and substituents R1-R7 all being defined as in formulas (1A) or (1B) below; pharmaceutical compositions and the uses of the atropisomers and compositions are inhibitors of PLK1- and PLK4 kinases, for example in the treatment of cancers. Formula (1A), formula (1B).
• Photocyclization of 4-(dialkylamino)-2-aryl-1-butenes
  作者：Hiromu Aoyama、Junichi Sugiyama、Masamichi Yoshida、Hiroaki Hatori、Akira Hosomi

  DOI：10.1021/jo00037a017

  日期：1992.5

  Irradiation of 4-(dialkylamino)-2-aryl-1-butenes gave cyclization products, 3-methyl-3-arylpyrrolidines, in high yields. These styrylamines formed fluorescent intramolecular exciplexes, but studies based on Stern-Volmer quenching for the fluorescence and the photoreaction suggested that the emissive exciplexes did not participate in the photoreaction.